How to generate license income from a drug screening assay

Loading Map....

Date(s) - 01/06/2017
2:30 pm - 2:45 pm

Danubius Hotel Helia, Budapest


Speaker:Daniel Gisi, IP Manager, Unitectra TTO, University of Basel
Topic:How to generate license income from a drug screening assay?
Excerpt:“With the end of the age of target patents, many universities have lost the ability to generate IP that effectively protects therapeutic agents. Many academic projects end with the validation of a drug target including a few tentative lead compounds as well as a scientific publication. Details of the target and assay get public and may be exploited by everybody. If the university does not run its own drug screening facility, the generation of valuable IP is entirely up to companies with their drug discovery capabilities based e.g. on high-throughput screening. In recent years, we have tried out several models of industry collaborations to remain involved and to secure our share in later drug IP. So far we have gained certain insights but feel that we have not yet found the egg of Columbus. We are interested in the experiences of our colleagues with similar approaches.”